Victoria Bray

Documentation of Advance Care Planning in Early Phase Cancer Clinical Trials: An Australian Single-Centre Experience

Nancy Huang, Joseph Descallar, Shapryns'kyĭ Vo, S. Lee et autres

BACKGROUND/OBJECTIVES: Patients with incurable cancers enrolled in early phase clinical trials often face uncertainty about prognosis, yet advance care planning (ACP) is frequently delayed. The objective of this study was to assess the documentation of ACP discussions among patients enrolled in early …

au (code pays fourni par la source)

Histopathological associations, molecular findings and clinical outcomes of patients with non-small cell lung carcinoma with MET alterations: a 3-year retrospective Australian case series

Jing Jing Li, Jawad Saab, Victoria Bray, Jonathan Williamson et autres

au (code pays fourni par la source)

OA08.04 Primary Endpoint Results from SHERLOCK: a Phase 2 trial of Sotorasib, Bevacizumab and Chemotherapy in Advanced KRAS G12C NSCLC

Chee Khoon Lee, Diansong Zhou, C. Brown, Victoria Bray et autres

gb, au, in, bb (code pays fourni par la source)

Implementation and evaluation of a nurse-led geriatric oncology model of care for older adults with lung cancer

Shalini Kavita Vinod, Katie Knight, Victoria Bray, Angela Khoo et autres

Adults aged 65+ years are expected to account for 60 % of all new cancer diagnoses by 2035 [1]. In Australia, the median age of people with lung cancer is 72 years [2]. Cancer in older adults can be challenging to treat …

au (code pays fourni par la source)

Real‐World Survival Outcomes of Patients With High PD‐L1 Advanced NSCLC Who Received Chemoimmunotherapy Versus Immunotherapy

Junipearl Cheng, C. McKay, Victoria Bray, Po Yee Yip et autres

BACKGROUND: Randomized studies have demonstrated superior overall survival (OS) of pembrolizumab (pembro), both alone and in combination with chemotherapy (chemo) over chemo alone in patients with programmed cell death ligand-1 (PD-L1) ≥ 50% advanced non-small cell lung cancer (NSCLC). We reviewed the …

au (code pays fourni par la source)

Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutations

Adel Shahnam, Alexander P. Davis, Lauren Julia Brown, I. Sullivan et autres

au (code pays fourni par la source)

Durvalumab consolidation after chemoradiotherapy in unresectable stage III non–small cell lung cancer: A real-world experience from the Australian subset of PACIFIC-R

Ben Markman, Steven Chuan-Hao Kao, Nick Pavlakis, Victoria Bray et autres

MICROABSTRACT: Australian subset of the multicentric PACIFIC-R study (NCT03798535) in patients with unresectable, stage III non-small cell lung cancer without progression following chemoradiotherapy, found a median progression-free survival of 22.4 months (95% confidence interval, 17.5 to 30.8) confirming clinical benefit of durvalumab …

au (code pays fourni par la source)

Durvalumab, Tremelimumab, and Platinum Chemotherapy in EGFR Mutation–Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE)

Chee Khoon Lee, Bin-Chi Liao, Shalini Subramaniam, Chao‐Hua Chiu et autres

Introduction EGFR -mutant NSCLC is associated with low mutation burden and low levels of PD-L1 expression. We conducted a phase 2 trial to determine the efficacy of durvalumab, tremelimumab, and platinum-pemetrexed in EGFR- mutant NSCLC after progression with EGFR tyrosine kinase inhibitors …

au, tw (code pays fourni par la source)

OA07.04 Optimising Care of Older Patients with Lung Cancer - An Innovative Nurse-led Model of Care

S. Vinod, Natalie Knox, Kellie A. Knight, Victoria Bray et autres

au, in (code pays fourni par la source)

ALKTERNATE: A Pilot Study Alternating Lorlatinib With Crizotinib in ALK-Positive NSCLC With Prior ALK Inhibitor Resistance

Malinda Itchins, Shirley Liang, Chris S. B. Brown, Tristan Alexandra Barnes et autres

Introduction: ALK-positive lung cancers represent a molecularly diverse disease. With drug exposure, driving selection pressure, and resistance pathways, disease relapse will emerge. There is compelling rationale to investigate novel treatment strategies, informed by dynamic circulating tumor DNA (ctDNA) monitoring. Methods: The single-arm, …

au, us (code pays fourni par la source)

The histopathological spectrum and molecular changes associated with KRAS G12C mutation in non-small cell lung carcinoma

Jing Jing Li, Xiao Juan Wu, Mahtab Farzin, Victoria Bray et autres

au (code pays fourni par la source)

A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE

Lavinia Tan, Chris S. B. Brown, Antony J. Mersiades, Chee Khoon Lee et autres

In this phase II, single arm trial (ACTRN12617000720314), we investigate if alternating osimertinib and gefitinib would delay the development of resistance to osimertinib in advanced, non-small cell lung cancer (NSCLC) with the epidermal growth factor receptor (EGFR) T790M mutation (n = 47) …

au (code pays fourni par la source)